ISC News: AUGUSTUS secondary analysis confirms safety of blood thinning agent

AUGUSTUS Maria Cecilia Bahit
Maria Cecilia Bahit. Photo by © AHA/Todd Buchanan 2020

Treatment with the blood thinner apixaban was associated with a lower risk of bleeding, death and hospitalisation compared with warfarin, regardless of history of prior stroke or blood clot. This secondary analysis of the AUGUSTUS trial was presented by Maria Cecilia Bahit from INECO Neurociencias in Rosario, Argentina, during a late-breaking session at the International Stroke Conference (ISC; 19–21 February, Los Angeles, USA).

First published in March 2019, AUGUSTUS found that treatment with apixaban without aspirin resulted in less bleeding and fewer deaths and hospitalisations than treatment with a vitamin K antagonist (like warfarin) plus aspirin among patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention treated with a P2Y12 inhibitor. The current study is a secondary analysis of the efficacy and safety outcomes of those treatments.

“We divided the AUGUSTUS study population into two groups: patients with prior stroke/transient ischaemic attack/thromboembolism and those with no prior stroke/transient ischaemic attack /thromboembolism,” said Bahit. “Apixaban was safer than warfarin, causing less major bleeding, resulting in less death or hospitalisation in both groups.”

In the multicentre study, 4,614 patients with atrial fibrillation and an acute coronary syndrome or those under­going percutaneous coronary intervention (PCI) with planned treatment with a P2Y12 inhibitor were randomly assigned to receive apixaban or a vitamin K antagonist and to receive aspirin or matching placebo for six months. Of the 4,581 patients with information available about prior stroke, 13.8% had prior stroke/transient ischaemic attack or thromboembolism.

Alluding to the findings, Bahit put forward that patients with prior stroke were at increased risk of ischaemic stroke, bleeding, hospitalisation or death compared with those with no prior stroke. Apixaban without aspirin was associated with the lowest rate of bleeding, death or hospitalisation, regardless of history of prior stroke.

Furthermore, she reported that the highest rate of bleeding was seen in patients who received the combination of a vitamin K antagonist plus aspirin, while the risk of bleeding was higher with aspirin than placebo among patients with no prior events.

There was no significant difference between aspirin and placebo observed between patients with and without prior stroke for other clinical outcomes.

“These results reinforce the main results of the AUGUSTUS trial by assuring physicians that even in a high-risk group of patients with prior stroke ’less is more.’ In other words, a strategy of apixaban plus a P2Y12 inhibitor without aspirin has the most favourable outcomes, and triple therapy—a vitamin K antagonist plus aspirin plus a P2Y12 inhibitor—should be avoided,” concluded Bahit.


Please enter your comment!
Please enter your name here